Despite advances in vaccine innovation to combat COVID-19, progress for other vaccine archetypes has been uneven, say senior partner Adam Sabow and colleagues. Excluding COVID-19 vaccines, the number of infectious disease vaccine programs plateaued. However, the response to the pandemic strengthened the vaccine business case and led to a 30 percent overall increase in candidates over the past five years. Stakeholders can consider five actions to harness the pandemic-driven momentum to accelerate innovation and tackle global health. Click through the interactive to see more.
To read the article, see “Beyond the pandemic: The next chapter of innovation in vaccines,” May 16, 2024.